Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Br J Haematol
    September 2026
  1. TAO Y, Falade AS, Ogbue OD, Adeoye O, et al
    Autologous haematopoietic stem cell transplant consolidation and survival outcomes in primary central nervous system lymphoma: Evidence from the National Cancer Database.
    Br J Haematol. 2026 Sep 30. doi: 10.1111/bjh.70861.
    >> Share

  2. CHOHAN KL, Feng L, Cochran H, Rosenberg M, et al
    Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma.
    Br J Haematol. 2026 Sep 27. doi: 10.1111/bjh.70854.
    >> Share

  3. YAGUCHI A, Fujimura J
    Generalised FDG-avid lymphadenopathy in Kikuchi-Fujimoto disease mimicking malignant lymphoma.
    Br J Haematol. 2026 Sep 25. doi: 10.1111/bjh.70827.
    >> Share

  4. GALLI E, Guarneri A, Corrente A, Portonera FM, et al
    Independent validation of the International Metabolic Prognostic Index (CAR-IMPI) in patients with aggressive diffuse large B-cell lymphoma treated with CAR-T.
    Br J Haematol. 2026 Sep 16. doi: 10.1111/bjh.70846.
    >> Share

  5. MERLI M, Bianchi B, Bibas M, Dalu D, et al
    Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi.
    Br J Haematol. 2026 Sep 4. doi: 10.1111/bjh.70793.
    >> Share

  6. WANG J, Gao Y, Grant SM, Hwang SR, et al
    Improved overall survival in classical Hodgkin lymphoma across therapeutic eras: A National Cancer Database study.
    Br J Haematol. 2026 Sep 1. doi: 10.1111/bjh.70776.
    >> Share

    August 2026
  7. AWAN FT, Liu R, Huang HH, Bye M, et al
    Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.
    Br J Haematol. 2026 Aug 31. doi: 10.1111/bjh.70803.
    >> Share

  8. GUIDEZ S, Belot A, Cherblanc F, Lesne B, et al
    Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.
    Br J Haematol. 2026 Aug 30. doi: 10.1111/bjh.70812.
    >> Share

  9. PIROSA MC, Brodtkorb M, Schar S, Wahlin BE, et al
    SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.
    Br J Haematol. 2026 Aug 30. doi: 10.1111/bjh.70801.
    >> Share

  10. BARGE L, Webb L, Pelecanos A, Waters N, et al
    LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.
    Br J Haematol. 2026 Aug 27. doi: 10.1111/bjh.70748.
    >> Share

  11. GALLAMINI A, Viviani S, Rapezzi D, Patti C, et al
    Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).
    Br J Haematol. 2026 Aug 26. doi: 10.1111/bjh.70763.
    >> Share

  12. OSBORNE W, Bielby H, Cwynarski K, El-Sharkawi D, et al
    The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.
    Br J Haematol. 2026 Aug 23. doi: 10.1111/bjh.70768.
    >> Share

  13. QIAO X, Tang Y, Yang Q, Yuan Q, et al
    Declining treatment-related and overall mortality in children with newly diagnosed advanced-stage non-Hodgkin lymphoma treated in a paediatric cancer centre during 2013-2024, Shanghai, China.
    Br J Haematol. 2026 Aug 21. doi: 10.1111/bjh.70772.
    >> Share

  14. JAWOREK CP, Supprian M, Brockelmann PJ, Tharmaseelan H, et al
    BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.
    Br J Haematol. 2026 Aug 21. doi: 10.1111/bjh.70771.
    >> Share

  15. CEPPI F, Abla O, Abramov D, Csomor J, et al
    Characteristics and outcome of T-cell/histiocyte-rich large B-cell lymphoma in childhood and adolescence: An international retrospective analysis.
    Br J Haematol. 2026 Aug 20. doi: 10.1111/bjh.70774.
    >> Share

  16. DICKINSON MJ, Berkahn L, Trotman J, Butler J, et al
    Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.
    Br J Haematol. 2026 Aug 19. doi: 10.1111/bjh.70777.
    >> Share

  17. KIM WS, Kim SJ, Jo JC, Yoon SE, et al
    Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.
    Br J Haematol. 2026 Aug 18. doi: 10.1111/bjh.70742.
    >> Share

  18. TOWNSEND W, Ghosh N, Hutchings M, Dickinson M, et al
    Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.
    Br J Haematol. 2026 Aug 17. doi: 10.1111/bjh.70741.
    >> Share

  19. GUI J, Yang A, Lin J, Che Q, et al
    Pathway alteration burden derived from whole-exome sequencing is associated with survival in primary central nervous system lymphoma.
    Br J Haematol. 2026 Aug 15. doi: 10.1111/bjh.70734.
    >> Share

  20. WINSA A, Lagerlof I, Ellin F, Fredriksson M, et al
    The association between inborn errors of immunity and Hodgkin lymphoma-A register-based case-control study in Sweden.
    Br J Haematol. 2026 Aug 12. doi: 10.1111/bjh.70743.
    >> Share

  21. PAVLOVSKY A, Fiad L, Fernandez I, Prates V, et al
    Long-term follow-up of PET/CT-adapted therapy after three cycles of ABVD for all stages of classic Hodgkin lymphoma: Results of the GATLA LH-05 trial.
    Br J Haematol. 2026 Aug 9. doi: 10.1111/bjh.70721.
    >> Share

  22. MUNKSGAARD L, Pedersen LM, Gjerdrum LMR
    Second primary cancers in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia-cumulative burden without generalized excess cancer risk.
    Br J Haematol. 2026 Aug 9. doi: 10.1111/bjh.70740.
    >> Share

  23. YOON H, Cho H, Song IH, Kim S, et al
    Prognostic impact of blood Epstein-Barr virus-DNA in patients with peripheral T-cell lymphoma, not otherwise specified.
    Br J Haematol. 2026 Aug 7. doi: 10.1111/bjh.70737.
    >> Share

  24. CHUNG K, Chron A, Kumar A, Modelevsky L, et al
    Bruton tyrosine kinase inhibitors plus chemoimmunotherapy in previously untreated younger mantle cell lymphoma patients: Single-centre clinical outcomes.
    Br J Haematol. 2026 Aug 7. doi: 10.1111/bjh.70732.
    >> Share

    July 2026
  25. SHIVAROV V
    Immune-related adverse events in Hodgkin lymphoma treated with pembrolizumab or nivolumab: A disease-restricted US Food and Drug Administration Adverse Event Reporting System (FAERS) pharmacovigilance analysis.
    Br J Haematol. 2026 Jul 29. doi: 10.1111/bjh.70724.
    >> Share

  26. SCHULZ E, Posch F, Friedrich K, Neumeister P, et al
    Comparison of outcomes after DA-EPOCH-R or GMALL high-intensity therapy for front-line treatment of Burkitt lymphoma: A retrospective cohort.
    Br J Haematol. 2026 Jul 25. doi: 10.1111/bjh.70730.
    >> Share

  27. MAKHANI S, Tudor T, Luttwak E, Alhomoud M, et al
    Immunoglobulin replacement after chimeric antigen receptor T-cell therapy in large B-cell lymphoma with hypogammaglobulinaemia: Secondary Center for International Blood and Marrow Transplant Research analysis.
    Br J Haematol. 2026 Jul 22. doi: 10.1111/bjh.70696.
    >> Share

  28. ABEYAKOON C, Wellard C, Murad V, Chung E, et al
    End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.
    Br J Haematol. 2026 Jul 17. doi: 10.1111/bjh.70689.
    >> Share

  29. WILLIAMS S, Lim YJ, Cooper R, Gamble C, et al
    Coronavirus disease 2019 (COVID-19) risk and evolving treatment patterns in follicular lymphoma during the pandemic: Insights from the PETReA trial.
    Br J Haematol. 2026 Jul 16. doi: 10.1111/bjh.70656.
    >> Share

  30. PORGES T, Levi T, Dann EJ, Aumann S, et al
    Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.
    Br J Haematol. 2026 Jul 14. doi: 10.1111/bjh.70682.
    >> Share

  31. WANG M, Jurczak W, Trneny M, Belada D, et al
    Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.
    Br J Haematol. 2026 Jul 12. doi: 10.1111/bjh.70620.
    >> Share

  32. CASEY DL, Renfro LA, Wu Y, McCarten K, et al
    Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial.
    Br J Haematol. 2026 Jul 8. doi: 10.1111/bjh.70625.
    >> Share

  33. HUNZEKER Z, de la Rosa FJ, Tyshevich A, Shavronskaya D, et al
    Mechanisms of resistance to macrophage checkpoint inhibitors in B-cell non-Hodgkin lymphoma for the British Journal of Haematology.
    Br J Haematol. 2026 Jul 7. doi: 10.1111/bjh.70668.
    >> Share

  34. YANG CF, Yeh YC, Hsu CY
    Prognostic impact of germline and somatic variants in lymphoma-associated haemophagocytic lymphohistiocytosis.
    Br J Haematol. 2026 Jul 7. doi: 10.1111/bjh.70674.
    >> Share

  35. VILLENEUVE PJA, Mozessohn L, Some NH, Mercer RE, et al
    Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting.
    Br J Haematol. 2026 Jul 6. doi: 10.1111/bjh.70632.
    >> Share

  36. MIKHAEEL NG, Bouziana S, Northend M, Brady JL, et al
    Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.
    Br J Haematol. 2026 Jul 3. doi: 10.1111/bjh.70653.
    >> Share

  37. ZHAO H, Kong L, Wang J, Gao W, et al
    The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.
    Br J Haematol. 2026 Jul 2. doi: 10.1111/bjh.70641.
    >> Share

  38. HU X, You L, Wang J, Yin X, et al
    Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.
    Br J Haematol. 2026 Jul 1. doi: 10.1111/bjh.70637.
    >> Share

  39. CARACCIOLO D, Lombardo MR, Reitano G, Napoli C, et al
    Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.
    Br J Haematol. 2026 Jul 1. doi: 10.1111/bjh.70649.
    >> Share

  40. KATSIMIGAS A, Werling M, Frederiksen CM, Vainer N, et al
    Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.
    Br J Haematol. 2026 Jul 1. doi: 10.1111/bjh.70651.
    >> Share

  41. MARCHISIO S, Yakymiv Y, Lin L, Ortolan E, et al
    Utility of combined CD39/CD73/CD38 expression for the detection of malignant T cells in Sezary syndrome.
    Br J Haematol. 2026;209:42-53.
    >> Share

  42. FALL C, Daudignon A, Valmary-Degano S, Mondet J, et al
    Optical genome mapping improves detection and characterisation of cytogenetic abnormalities in non-Hodgkin lymphomas.
    Br J Haematol. 2026;209:31-41.
    >> Share

    June 2026
  43. EIGENDORFF F, Gorke F, Zeremski V, Wollnitza S, et al
    Response-adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort.
    Br J Haematol. 2026 Jun 25. doi: 10.1111/bjh.70633.
    >> Share

  44. CERIANI L, Milan L, Cascione L, Di Rocco A, et al
    Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study.
    Br J Haematol. 2026 Jun 16. doi: 10.1111/bjh.70614.
    >> Share

  45. ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
    Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience.
    Br J Haematol. 2026 Jun 15. doi: 10.1111/bjh.70631.
    >> Share

  46. CASERTA S, Martino EA, Vigna E, Bruzzese A, et al
    Minimal residual disease in diffuse large B-cell lymphoma after first-line therapy: Defining the continuum from metabolic remission to molecular clearance.
    Br J Haematol. 2026 Jun 14. doi: 10.1111/bjh.70619.
    >> Share

  47. ZHANG M, Chen Y
    Response alone does not define optimal bridging before brexucabtagene autoleucel in mantle cell lymphoma.
    Br J Haematol. 2026 Jun 14. doi: 10.1111/bjh.70615.
    >> Share

  48. EYRE TA
    Where next for BTKi-BCL2i combinations in mantle cell lymphoma?
    Br J Haematol. 2026 Jun 14. doi: 10.1111/bjh.70621.
    >> Share

  49. ZHOU ZZ, Lu JC, Wang Z, Chen RH, et al
    Machine learning-driven investigation on liquid-liquid phase separation-related prognostic signature in diffuse large B-cell lymphoma.
    Br J Haematol. 2026 Jun 5. doi: 10.1111/bjh.70601.
    >> Share

  50. LU Y, Preston G, Laing G, Scott P, et al
    Cow hooves and clover: Unusual morphology of peripheral T-cell lymphoma.
    Br J Haematol. 2026 Jun 2. doi: 10.1111/bjh.70566.
    >> Share

  51. ZHAO Y, Guo J, Wang X, Cao L, et al
    Concurrent antiviral-immunochemotherapy strategy safely overcomes high hepatitis B viral load barrier in diffuse large B-cell lymphoma: A multicentre cohort study.
    Br J Haematol. 2026 Jun 2. doi: 10.1111/bjh.70584.
    >> Share

  52. SABATTINI E, Ascani S, Ciavarella S, Di Napoli A, et al
    Mediastinal grey zone lymphomas: Results of the expert pathological review analysis of a case series enrolled in the multicentre BIOGZL-2020 study in Italy.
    Br J Haematol. 2026;208:2016-2025.
    >> Share

    May 2026
  53. FRUTOS DIAZ-ALEJO J, Diaz de la Pinta FJ, Pavia Pascual L, Manso R, et al
    DNMT3A variants are associated with the development of nodal TFH cell lymphoma, angioimmunoblastic-type after solid tumour occurrence.
    Br J Haematol. 2026 May 24. doi: 10.1111/bjh.70576.
    >> Share

  54. CHENG Q, Zhu Y, Sheng K, Zhou J, et al
    Long-term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T-lymphoblastic lymphoma.
    Br J Haematol. 2026 May 24. doi: 10.1111/bjh.70581.
    >> Share

  55. GOODALL E, Palmer J, Martynchyk A, Waters N, et al
    Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.
    Br J Haematol. 2026 May 15. doi: 10.1111/bjh.70550.
    >> Share

  56. BASTOS-BOENTE M, Medina-Herrera A, Navarro-Bailon A, Ferrero S, et al
    Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).
    Br J Haematol. 2026 May 14. doi: 10.1111/bjh.70535.
    >> Share

  57. SIMONSEN MR, Jerm MB, Johannesen TB, Enerstvedt L, et al
    Population-based survival after mantle cell lymphoma in Norway and Denmark: Limited impact of earlier BTKi access.
    Br J Haematol. 2026 May 12. doi: 10.1111/bjh.70538.
    >> Share

  58. SERNA A, Navarro V, Abrisqueta P
    Response to 'Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma'.
    Br J Haematol. 2026 May 11. doi: 10.1111/bjh.70523.
    >> Share

  59. YAN C, Liu J
    Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma.
    Br J Haematol. 2026 May 7. doi: 10.1111/bjh.70522.
    >> Share

  60. AMIOT Q, Dejean ALE, Navarrot JC, Arnautou P, et al
    An atypical bilobed and binucleated splenic marginal zone lymphoma.
    Br J Haematol. 2026 May 7. doi: 10.1111/bjh.70514.
    >> Share

    April 2026
  61. LAM HPJ, Arulogun S, Mikhaeel NG, Brady JL, et al
    Glofitamab in refractory Burkitt lymphoma-type post-transplant lymphoproliferative disorder.
    Br J Haematol. 2026 Apr 28. doi: 10.1111/bjh.70519.
    >> Share

  62. DINGLI S, Rothweiler P, Corraes AMS, Atallah-Yunes A, et al
    Lymphocyte dynamics after CAR-T therapy for non-Hodgkin lymphoma.
    Br J Haematol. 2026 Apr 21. doi: 10.1111/bjh.70502.
    >> Share

  63. VALCARCEL B, Utsunomiya A, Otsuka M, Miyahara M, et al
    Distribution of adult T-cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.
    Br J Haematol. 2026 Apr 15. doi: 10.1111/bjh.70494.
    >> Share

  64. ARAI Y, Jo T, Sato T, Sakurai M, et al
    Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.
    Br J Haematol. 2026 Apr 15. doi: 10.1111/bjh.70488.
    >> Share

  65. MARTYNCHYK A, Chong G, Khor R, Lee D, et al
    Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naive follicular lymphoma: Results from the phase II 'FLUORO' study.
    Br J Haematol. 2026 Apr 8. doi: 10.1111/bjh.70468.
    >> Share

  66. TIAN Z, Deng Z, Han F, Yu L, et al
    An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL/SLL.
    Br J Haematol. 2026;208:1287-1295.
    >> Share

  67. MARTINS F, Calvao J
    Mycosis fungoides and Sezary syndrome.
    Br J Haematol. 2026;208:1207-1210.
    >> Share

    March 2026
  68. CASERTA S, Martino EA, Skafi M, Alvaro ME, et al
    Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration.
    Br J Haematol. 2026 Mar 29. doi: 10.1111/bjh.70458.
    >> Share

  69. LUAN M, Jia R, Wang D, Zhang F, et al
    Early prediction of adult lymphoma-associated haemophagocytic lymphohistiocytosis using an interpretable machine learning model.
    Br J Haematol. 2026 Mar 23. doi: 10.1111/bjh.70447.
    >> Share

  70. CLIFF ERS, McKeague S, Dickinson MJ
    Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma's new era.
    Br J Haematol. 2026 Mar 23. doi: 10.1111/bjh.70451.
    >> Share

  71. SOLOW M, Owen C, Stewart C, Cao JQ, et al
    Limited diagnostic utility of bone marrow sampling in PET-defined limited-stage follicular lymphoma.
    Br J Haematol. 2026 Mar 17. doi: 10.1111/bjh.70440.
    >> Share

  72. DE RE V, Lopci E, Brisotto G, Elia C, et al
    Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.
    Br J Haematol. 2026 Mar 12. doi: 10.1111/bjh.70423.
    >> Share

  73. CHOLACK GA, Mwangi R, Vodicka P, Habermann TM, et al
    Family history of haematological malignancy and prognosis across non-Hodgkin lymphoma subtypes.
    Br J Haematol. 2026 Mar 10. doi: 10.1111/bjh.70397.
    >> Share

  74. RIGOLIN GM, Soddu S, Dondolin R, Frustaci AM, et al
    Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA wo
    Br J Haematol. 2026 Mar 10. doi: 10.1111/bjh.70401.
    >> Share

  75. NASIBOV T, Cunningham A, Sarpong L, Smyth E, et al
    Fibrin-associated large B-cell lymphoma presenting in a renal transplant patient.
    Br J Haematol. 2026 Mar 10. doi: 10.1111/bjh.70417.
    >> Share

  76. O'REILLY MA, Wilson W, Maybury B, Kuhnl A, et al
    Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.
    Br J Haematol. 2026 Mar 8. doi: 10.1111/bjh.70357.
    >> Share

  77. FU YC, Liu LP, Zhou YP, Yang MH, et al
    From genetic variants to therapeutic targets: A study reveals MMS19 and HLA genes in Hodgkin lymphoma pathogenesis.
    Br J Haematol. 2026 Mar 6. doi: 10.1111/bjh.70326.
    >> Share

  78. HWANG YY, Au-Yeung R, Kwong YL
    Fibrin-associated large B-cell lymphoma occurring in an ancient retroperitoneal schwannoma.
    Br J Haematol. 2026 Mar 5. doi: 10.1111/bjh.70408.
    >> Share

  79. TUTEJA SK, Wlodaver A, Kirschmann D, Caparelli E, et al
    Insights into the novel EEF1D::ALK fusion transcript in FISH-negative ALK-positive anaplastic large cell lymphoma.
    Br J Haematol. 2026 Mar 3. doi: 10.1111/bjh.70410.
    >> Share

  80. BAGNOLI F, Calabrese De Feo J, Ricci F, Corrado F, et al
    Bendamustine in combination with gemcitabine and vinorelbine as salvage regimen for relapsed or refractory peripheral T-cell lymphomas: A retrospective single-centre experience.
    Br J Haematol. 2026;208:916-925.
    >> Share

  81. STADLER R, Quaglino P, Roccuzzo G
    How I manage mycosis fungoides and Sezary syndrome: Current controversies and unmet needs.
    Br J Haematol. 2026;208:864-873.
    >> Share

  82. MATOS DM
    Lymph node biopsy indications: Challenges in determining the 'when'.
    Br J Haematol. 2026;208:837-840.
    >> Share

    February 2026
  83. LIU Y, Zhang J, Wang L, Liang Z, et al
    Association between body mass index and outcomes in lymphoma-associated haemophagocytic lymphohistiocytosis: A retrospective multicentre cohort study of Jiangsu Cooperative Lymphoma Group (JCLG).
    Br J Haematol. 2026 Feb 27. doi: 10.1111/bjh.70406.
    >> Share

  84. ARGNANI L, Stefoni V, Casadei B, Pelusi C, et al
    Immune-related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors.
    Br J Haematol. 2026 Feb 26. doi: 10.1111/bjh.70402.
    >> Share

  85. MILES B, Mao D, Vardhanabhuti S, Bedognetti D, et al
    Predictive value of MRD monitoring by BCR clonality in the ZUMA-7 randomized clinical trial for CAR T therapy in r/r lymphoma.
    Br J Haematol. 2026 Feb 24. doi: 10.1111/bjh.70375.
    >> Share

  86. LIGIA S, Assanto GM, Soriano T, Cappelli LV, et al
    Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.
    Br J Haematol. 2026 Feb 20. doi: 10.1111/bjh.70390.
    >> Share

  87. POUTHIER M, Garnier N, Leruste A, Rigaud C, et al
    Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real-world study.
    Br J Haematol. 2026 Feb 17. doi: 10.1111/bjh.70379.
    >> Share

  88. PENA M, Lazzari L, Martinez DF, Ciceri F, et al
    Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study.
    Br J Haematol. 2026 Feb 12. doi: 10.1111/bjh.70367.
    >> Share

  89. WEI C, Zhang Y, Zhao D, Zhang W, et al
    Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution.
    Br J Haematol. 2026 Feb 11. doi: 10.1111/bjh.70363.
    >> Share

  90. ZADRO A, Arribas A, Colombo MV, Cannas E, et al
    A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHL.
    Br J Haematol. 2026;208:716-721.
    >> Share

    January 2026
  91. SONG J, Jiang H, Ding K, Liu H, et al
    Zanubrutinib, lenalidomide, rituximab, temozolomide +/- methotrexate as first-line treatment for primary central nervous system lymphoma: A prospective, open-label, multicentre clinical trial.
    Br J Haematol. 2026 Jan 26. doi: 10.1111/bjh.70335.
    >> Share

  92. YI S, Cao J, Feng R, Zhou K, et al
    A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.
    Br J Haematol. 2026 Jan 22. doi: 10.1111/bjh.70334.
    >> Share

  93. ANGEL S, Marc B, Victor N, Patricia LP, et al
    Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.
    Br J Haematol. 2026 Jan 20. doi: 10.1111/bjh.70298.
    >> Share

  94. GOWDY SC, Flerlage JE, Seelisch J, Palese M, et al
    Prognostic role of PET/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group.
    Br J Haematol. 2026 Jan 14. doi: 10.1111/bjh.70329.
    >> Share

  95. KIM K, Shah R, Ayers A, Ahmed S, et al
    Clinical trial access after CAR T-cell therapy failure in relapsed/refractory large B-cell lymphoma.
    Br J Haematol. 2026 Jan 11. doi: 10.1111/bjh.70325.
    >> Share

  96. UENO T, Yoshimitsu M, Sameshima M, Nagano T, et al
    Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2026 Jan 5. doi: 10.1111/bjh.70301.
    >> Share

  97. YILDIRIM N, Anders M, Smith VM, Jayne S, et al
    The BH3-only protein NOXA is essential for apoptosis induction by BH3-mimetics targeting BCL2 or BCL-X(L) in DLBCL.
    Br J Haematol. 2026;208:96-105.
    >> Share

    December 2025
  98. TERAO T, Yoshida I, Kobayashi H, Urata T, et al
    Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: A multicentre real-world study.
    Br J Haematol. 2025 Dec 26. doi: 10.1111/bjh.70280.
    >> Share

  99. ZILIOLI VR, Tucci A, Spina M, Merli F, et al
    The importance of assessing the fitness of older patients with newly diagnosed diffuse large B-cell lymphoma and classic Hodgkin lymphoma.
    Br J Haematol. 2025 Dec 25. doi: 10.1111/bjh.70290.
    >> Share

  100. CHOY JP, Cheah CY
    T-cell/histiocyte-rich large B-cell lymphoma in the era of novel immunotherapy: A focused review.
    Br J Haematol. 2025 Dec 23. doi: 10.1111/bjh.70294.
    >> Share

  101. HUGUET M, Morgades M, Rivas-Delgado A, Bastos-Oreiro M, et al
    Validation of prognostic scores in patients with HIV-related diffuse large B-cell lymphoma: The value of peripheral blood parameters-A study from the Spanish Lymphoma Group GELTAMO.
    Br J Haematol. 2025 Dec 23. doi: 10.1111/bjh.70287.
    >> Share

  102. ZHONG Y, Bult J, Veltmaat N, de Jesus FM, et al
    Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients.
    Br J Haematol. 2025 Dec 18. doi: 10.1111/bjh.70296.
    >> Share

  103. KIRK A, James B, Feltbower RG, Mushtaq T, et al
    Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).
    Br J Haematol. 2025 Dec 18. doi: 10.1111/bjh.70286.
    >> Share

  104. PICARDI M, Vincenzi A, Pugliese N, Giordano C, et al
    The progression at 24 months (POD24) induces a high risk of transformation of follicular lymphoma: A systematic biopsy verification.
    Br J Haematol. 2025 Dec 3. doi: 10.1111/bjh.70277.
    >> Share

  105. YU QQ, Quan C, Li Y, Sun R, et al
    Paradoxical role and therapeutic potential of autophagy in lymphomas.
    Br J Haematol. 2025;207:2270-2279.
    >> Share

    November 2025
  106. DONATI G, Nicoli P, Miele F, Podini P, et al
    Combinatorial targeting of MYC/BCL2-associated vulnerabilities in high-grade B-cell lymphoma.
    Br J Haematol. 2025 Nov 18. doi: 10.1111/bjh.70249.
    >> Share

  107. THIRUVENGADAM SK, Popplewell LL, Herrera AF, Mei M, et al
    Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study.
    Br J Haematol. 2025 Nov 18. doi: 10.1111/bjh.70212.
    >> Share

  108. HESS G, Eyre TA, Jen MH, Zhang J, et al
    A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor.
    Br J Haematol. 2025 Nov 17. doi: 10.1111/bjh.70237.
    >> Share

  109. HARROP S, Minson A, Steiner TM, Neeson PJ, et al
    Bispecific antibody combination therapies in diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Nov 7. doi: 10.1111/bjh.70228.
    >> Share

  110. JUNG JM, Choi ME, Moon IJ, Won CH, et al
    Systemic immune-inflammation index and pan-immune value as prognostic indicators of clinical outcomes in mycosis fungoides: A retrospective cohort study.
    Br J Haematol. 2025;207:1902-1911.
    >> Share

    October 2025
  111. LOSSOS IS, Martin JL, Chapman JR, Pongas GN, et al
    Peripheral blood involvement in extra-nodal marginal zone lymphoma.
    Br J Haematol. 2025 Oct 31. doi: 10.1111/bjh.70232.
    >> Share

  112. GORDON MJ, Lakhotia R, Pittaluga S, Pack SD, et al
    Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma.
    Br J Haematol. 2025 Oct 30. doi: 10.1111/bjh.70234.
    >> Share

  113. BRAENDSTRUP P, Mortensen TB, El-Galaly TC, Moller MB, et al
    Outcome of T-cell/histiocyte-rich large B-cell lymphoma-A Danish nationwide matched cohort study.
    Br J Haematol. 2025 Oct 28. doi: 10.1111/bjh.70217.
    >> Share

  114. SHICHIJO T, Tatetsu H, Higuchi Y, Miyakawa T, et al
    Prognostic impact of valemetostat in relapsed/refractory adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2025 Oct 23. doi: 10.1111/bjh.70219.
    >> Share

  115. SAROSIEK S, Suarez U, Fernandez-Turizo M, Sarosiek KA, et al
    BCL-2 inhibition in Waldenstrom macroglobulinaemia and marginal zone lymphoma.
    Br J Haematol. 2025 Oct 19. doi: 10.1111/bjh.70208.
    >> Share

  116. ZHANG X, Wang L, Kuang N, Yang J, et al
    Immune reconstitution after CD7 CAR-T cell therapy for refractory/relapsed acute T-lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T-ALL/LBL).
    Br J Haematol. 2025 Oct 19. doi: 10.1111/bjh.70201.
    >> Share

  117. SALVINO MA, Luisi FAV, Pianovski MA, Fagioli F, et al
    A phase I/II study of brentuximab vedotin + AVD in paediatric patients with advanced Hodgkin lymphoma.
    Br J Haematol. 2025 Oct 14. doi: 10.1111/bjh.70207.
    >> Share

  118. VONBERG FW, Rice-Wilson D, Malik I, Keddie S, et al
    Transient imaging changes accompany 'spinal ICANS' following CAR T-cell therapy for large B-cell lymphoma in adults.
    Br J Haematol. 2025 Oct 13. doi: 10.1111/bjh.70206.
    >> Share

  119. MUNZ N, Arribas AJ, Bordone Pittau R, Simonetta F, et al
    Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Oct 7. doi: 10.1111/bjh.70185.
    >> Share

  120. HU X, Li L, Nkwocha J, Vasiyani H, et al
    Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines.
    Br J Haematol. 2025 Oct 5. doi: 10.1111/bjh.70188.
    >> Share

  121. CHIRIAC R, Baseggio L
    Reed-Sternberg-like cells in central nervous system relapse of diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Oct 2. doi: 10.1111/bjh.70174.
    >> Share

  122. SUH M, Hyung J, Park CS, Go H, et al
    Prognostic significance of pretransplant (18)F-FDG PET/CT metrics in relapsed/refractory diffuse large B-cell lymphoma with partial response to salvage chemotherapy prior to autologous stem cell transplantation.
    Br J Haematol. 2025 Oct 1. doi: 10.1111/bjh.70186.
    >> Share

  123. SHENG X, Wang D, Li S, Li B, et al
    Targeting small ubiquitin-related modifier-specific protease 2 attenuates tumour progression and orchestrates the tumour immune microenvironment in diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Oct 1. doi: 10.1111/bjh.70187.
    >> Share

  124. LYNCH RC, Cassaday RD, Smith SD, Cowan AJ, et al
    Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2025;207:1599-1603.
    >> Share

  125. WU R, Li Y, Zhang D, Liu T, et al
    Population pharmacokinetics of high-dose methotrexate and 7-hydroxy methotrexate in Chinese adults with primary central nervous system lymphoma.
    Br J Haematol. 2025;207:1622-1627.
    >> Share

  126. MARTINEZ ALCALA R, Lei Y, Visser L, Diepstra A, et al
    Programmed cell death-1 inhibition activates CD4 T cells in a novel in vitro model of Hodgkin lymphoma.
    Br J Haematol. 2025;207:1643-1647.
    >> Share

  127. TRIANTAFILO N, Chowdhury A, Thiruvengadam S, Herrera AF, et al
    Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphoma.
    Br J Haematol. 2025;207:1668-1672.
    >> Share

    September 2025
  128. KALASHNIKOV I, Reunamo T, Tanskanen T, Viisanen L, et al
    Transformation and causes of death in follicular lymphoma: A Finnish nationwide population-based study.
    Br J Haematol. 2025 Sep 25. doi: 10.1111/bjh.70181.
    >> Share

  129. OLSZEWSKI AJ, Treaba DO, Winter A, Donnelly S, et al
    Loncastuximab tesirine elicits complete responses in secondary central nervous system lymphoma.
    Br J Haematol. 2025 Sep 21. doi: 10.1111/bjh.70178.
    >> Share

  130. PATZKE S, Cascione L, Melhus KB, Munz N, et al
    Comprehensive analysis of (177)Lu-lilotomab satetraxetan in lymphoma cell lines: Implications for precision radioimmunotherapy and combination schemes.
    Br J Haematol. 2025 Sep 18. doi: 10.1111/bjh.70143.
    >> Share

  131. LI Y, Jin L, Liu W, Liu Y, et al
    Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.
    Br J Haematol. 2025 Sep 16. doi: 10.1111/bjh.70097.
    >> Share

  132. BAHABRI AS, Lau C, Kim VHD, Alexander S, et al
    Incidence and impact of prior history of serious infection in paediatric lymphoma: A population-based study.
    Br J Haematol. 2025 Sep 15. doi: 10.1111/bjh.70157.
    >> Share

  133. KUHNL A, Bouziana S, Barrington SF, Galani S, et al
    MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.
    Br J Haematol. 2025 Sep 11. doi: 10.1111/bjh.70137.
    >> Share

  134. VODICKA P, Hamova I, Velasova A, Kupcova K, et al
    Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.
    Br J Haematol. 2025 Sep 7. doi: 10.1111/bjh.70128.
    >> Share

  135. CHAGANTI S, Dulobdas V, Wilson MR, Tucker D, et al
    Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper.
    Br J Haematol. 2025 Sep 5. doi: 10.1111/bjh.70018.
    >> Share

  136. SONG Y, Zou D, Yang H, Wu J, et al
    Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study.
    Br J Haematol. 2025 Sep 1. doi: 10.1111/bjh.20122.
    >> Share

  137. NORDKIN M, Fadaos N, Leiba R, Sharon-Horesh N, et al
    Duration of anti-CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2-year maintenance paradigm.
    Br J Haematol. 2025;207:1104-1107.
    >> Share

  138. BARONE A, De Philippis C, Stella F, Dodero A, et al
    Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes.
    Br J Haematol. 2025;207:956-964.
    >> Share

  139. JO T, Arai Y, Shimizu T, Kitawaki T, et al
    Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post-CAR-T-cell therapy.
    Br J Haematol. 2025;207:1002-1010.
    >> Share

  140. JOHNSTONE P, Higgins M, Prince HM, Lade S, et al
    Large-cell transformation of mycosis fungoides: Patterns of care and patient outcomes.
    Br J Haematol. 2025;207:824-833.
    >> Share

    August 2025
  141. MARIOTTI J, Pinton C, Giordano L, Taurino D, et al
    Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis.
    Br J Haematol. 2025 Aug 31. doi: 10.1111/bjh.70091.
    >> Share

  142. KLEINSTERN G, Robinson DP, Abu Seir R, Perlman R, et al
    European-based polygenic risk score and genome-wide association study of B-cell non-Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs.
    Br J Haematol. 2025 Aug 31. doi: 10.1111/bjh.70125.
    >> Share

  143. LUMINARI S, Barbieri E, Nizzoli ME
    Towards a chemo-free approach for follicular lymphoma.
    Br J Haematol. 2025 Aug 30. doi: 10.1111/bjh.70126.
    >> Share

  144. YU F, Yu X, Hu X, Jiang E, et al
    Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025 Aug 26. doi: 10.1111/bjh.70102.
    >> Share

  145. KOCA O, Eskazan AE
    Refining the risk stratification in advanced-stage classical Hodgkin lymphoma: A critical analysis of clinical prediction models.
    Br J Haematol. 2025 Aug 22. doi: 10.1111/bjh.70115.
    >> Share

  146. TE VRUGT M, Newman H, Teachey DT, Burkhardt B, et al
    T-cell lymphoblastic lymphoma in children, adolescents and young adults.
    Br J Haematol. 2025 Aug 13. doi: 10.1111/bjh.70053.
    >> Share

  147. MORIMOTO S, Jo T, Kitawaki T, Sakamoto T, et al
    Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Aug 11. doi: 10.1111/bjh.70090.
    >> Share

  148. TRAB T, Ranadottir T, Chanchiri I, Ludvigsen Al-Mashhadi A, et al
    Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population-based study.
    Br J Haematol. 2025 Aug 8. doi: 10.1111/bjh.70082.
    >> Share

    July 2025
  149. CARPIO C, de la Cruz-Vicente F, Garcia-Sanz R, Zeberio I, et al
    A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial.
    Br J Haematol. 2025 Jul 25. doi: 10.1111/bjh.70028.
    >> Share

  150. HOSSAIN NM, Ahn KW, Patel J, Lian Q, et al
    Chimeric antigen receptor T-cell therapy for high-grade B-cell lymphoma NOS.
    Br J Haematol. 2025 Jul 22. doi: 10.1111/bjh.70020.
    >> Share

  151. REGAZZO G, Vari G, Marchesi F, Diaz Mendez AB, et al
    A predictive serum miRNA signature impacts diffuse large B-cell lymphoma cell viability via inhibition of EGLN1 and TXNRD1 regulators of ferroptosis.
    Br J Haematol. 2025 Jul 20. doi: 10.1111/bjh.70017.
    >> Share

  152. KHAVANDI MM, Strati P, Habibollahi P
    Minimally invasive percutaneous lymphangiography and embolisation for spontaneous chyle leaks in patients with lymphoma.
    Br J Haematol. 2025 Jul 15. doi: 10.1111/bjh.70007.
    >> Share

  153. SEVERINSEN FT, Simonsen MR, Futtrup Maksten E, Jakobsen LH, et al
    Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study.
    Br J Haematol. 2025 Jul 13. doi: 10.1111/bjh.20262.
    >> Share

  154. PARTANEN A, Ronka A, Anttalainen A, Ukkola-Vuoti L, et al
    Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival.
    Br J Haematol. 2025 Jul 10. doi: 10.1111/bjh.20253.
    >> Share

  155. MOIOLI A, Visco C
    We are on the right track for mantle cell lymphoma.
    Br J Haematol. 2025 Jul 6. doi: 10.1111/bjh.20259.
    >> Share

  156. ALZAHRANI M, Gerrie AS, Sehn LH, Scott DW, et al
    Therapeutic advances and gradual improvement in overall survival in mantle cell lymphoma over four decades.
    Br J Haematol. 2025 Jul 2. doi: 10.1111/bjh.20239.
    >> Share

  157. GASCON P, Frankel D, Fritz S, Comet A, et al
    Vitrectomy as a rapid diagnostic tool for lymphoma: Cytology and flow cytometry approach.
    Br J Haematol. 2025 Jul 1. doi: 10.1111/bjh.20250.
    >> Share

  158. CASSANELLO G, Luttwak E, Brown S, Devlin SM, et al
    Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.
    Br J Haematol. 2025 Jul 1. doi: 10.1111/bjh.20234.
    >> Share

  159. HANAJIRI R, Wakabayashi H, Ishigiwa K, Ohara F, et al
    Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion.
    Br J Haematol. 2025;207:180-188.
    >> Share

    June 2025
  160. SHARP J, Zhao Q, Voorhees TJ, Bond DA, et al
    Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma.
    Br J Haematol. 2025 Jun 30. doi: 10.1111/bjh.20240.
    >> Share

  161. MOLINA F, Sureda A, Mussetti A
    Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed/refractory large B-cell lymphoma, including in the CAR T-cell era.
    Br J Haematol. 2025 Jun 25. doi: 10.1111/bjh.20217.
    >> Share

  162. WEI C, Zhang Y, Zhao D, Zhang W, et al
    Germline defects of familial haemophagocytic lymphohistiocytosis-Related genes may represent a predisposing factor for mature T- and natural killer-cell lymphoma.
    Br J Haematol. 2025 Jun 23. doi: 10.1111/bjh.20231.
    >> Share

  163. UPPAL M, Joseph A, Drill E, Hamlin P, et al
    Predictors of outcomes with covalent BTK inhibitor treatment in relapsed/refractory TP53-mutant mantle cell lymphoma.
    Br J Haematol. 2025 Jun 23. doi: 10.1111/bjh.20202.
    >> Share


  164. Correction to "Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma".
    Br J Haematol. 2025 Jun 19. doi: 10.1111/bjh.20237.
    >> Share

  165. CHUNG K, Ng LS, Yee CI, Bansal R, et al
    Impact of granulocyte colony-stimulating factor on safety of chimeric antigen receptor-T-cell therapy in non-Hodgkin lymphoma.
    Br J Haematol. 2025 Jun 17. doi: 10.1111/bjh.20207.
    >> Share

  166. YILMAZ U, Terzi Demirsoy E, Keklik Karadag F, Hatipoglu U, et al
    Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohort.
    Br J Haematol. 2025 Jun 16. doi: 10.1111/bjh.20111.
    >> Share

  167. HUIYING Z, Congwei J, Yue C, Lu Z, et al
    Arborising telangiectasia in intravascular large B-cell lymphoma.
    Br J Haematol. 2025 Jun 12. doi: 10.1111/bjh.20172.
    >> Share

  168. CHIRIAC R, Baseggio L
    Chronic lymphocytic leukaemia extravaganza: Vacuolated lymphoma cells.
    Br J Haematol. 2025 Jun 11. doi: 10.1111/bjh.20162.
    >> Share

  169. NOVO M, Frascione PMM, Castellino A, Marcheselli L, et al
    Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).
    Br J Haematol. 2025 Jun 10. doi: 10.1111/bjh.20204.
    >> Share

  170. DITTUS C, Weinstock MJ, Barnes J, Sandoval-Sus J, et al
    Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2025 Jun 3. doi: 10.1111/bjh.20177.
    >> Share

  171. SORIAL MN, Han JX, Koh MJ, Boussi L, et al
    Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study.
    Br J Haematol. 2025;206:1664-1677.
    >> Share

    May 2025
  172. GLEESON M, Gonzalez Arias C, Cunningham D, Peckitt C, et al
    The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial.
    Br J Haematol. 2025 May 26. doi: 10.1111/bjh.20160.
    >> Share

  173. HARLAY V, Gallardo C, Beaufils N, Astier A, et al
    Evaluation of MYD88 p.L265P detection by digital droplet polymerase chain reaction in cerebrospinal fluid for integrated diagnosis of primary large B-cell lymphoma of the central nervous system.
    Br J Haematol. 2025 May 25. doi: 10.1111/bjh.20167.
    >> Share

  174. SRINIVASAN S, Narayan A, Dhamne C, Chichra A, et al
    Combination of fixed low-dose nivolumab and bendamustine in children with high-risk relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2025 May 20. doi: 10.1111/bjh.20148.
    >> Share

  175. CHAGANTI S, Fox CP, Maybury BD, Burton C, et al
    Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2025 May 19. doi: 10.1111/bjh.20129.
    >> Share

  176. HAUJIR A, Tostesen M, El-Galaly TC, Larsen TS, et al
    Effectiveness of rituximab and biosimilar rituximab in untreated diffuse large B-cell lymphoma, a Danish population-based analysis.
    Br J Haematol. 2025 May 15. doi: 10.1111/bjh.20155.
    >> Share

  177. HAFI M, Iyengar S, Wotherspoon A, Cunningham D, et al
    Involvement of the gastrointestinal tract by mantle cell lymphoma.
    Br J Haematol. 2025 May 15. doi: 10.1111/bjh.20048.
    >> Share

  178. LOWE EJ, Woessmann W
    Anaplastic large cell lymphoma in children and adolescents.
    Br J Haematol. 2025 May 12. doi: 10.1111/bjh.20154.
    >> Share

  179. TANG C, Downie C, Sagoo MS, Pringle E, et al
    An international real-world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators.
    Br J Haematol. 2025 May 6. doi: 10.1111/bjh.20115.
    >> Share

  180. AOKI T, Salib M, Suleman A, Ghanem N, et al
    Distinct characteristics and social determinants in adult T-cell leukaemia/lymphoma patients at a tertiary cancer centre in Canada.
    Br J Haematol. 2025 May 6. doi: 10.1111/bjh.20132.
    >> Share

  181. HARROP S, Casan J, Rose H, Sullivan M, et al
    Heterozygous germline TET2 loss-of-function variants associated with an ALPS-like phenotype.
    Br J Haematol. 2025;206:1330-1334.
    >> Share

    April 2025
  182. VALLET N, Picou F, Arbion F, Doyen H, et al
    Aberrant antioxidant responses in B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2025 Apr 30. doi: 10.1111/bjh.20108.
    >> Share

  183. HERBAUX C, Bachy E, Bouabdallah R, Guidez S, et al
    Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
    Br J Haematol. 2025 Apr 26. doi: 10.1111/bjh.20109.
    >> Share

  184. HARRYSSON S, Eloranta S, Antonilli S, Runason Simonsen M, et al
    Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies.
    Br J Haematol. 2025 Apr 23. doi: 10.1111/bjh.20104.
    >> Share

  185. SUZUKI T, Fujii K, Matsunaga N, Sasaki H, et al
    Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Apr 22. doi: 10.1111/bjh.20099.
    >> Share

  186. NIRMAL G, Thankamony P, Nair RA, Nair M, et al
    Resource-adapted strategies in the management of paediatric Burkitt lymphoma in low- and middle-income country setting and outcomes: An Indian centre experience.
    Br J Haematol. 2025 Apr 22. doi: 10.1111/bjh.20093.
    >> Share

  187. CERIANI L, Milan L, Chauvie S, Zucca E, et al
    Understandings 18 FDG PET radiomics and its application to lymphoma.
    Br J Haematol. 2025 Apr 15. doi: 10.1111/bjh.20074.
    >> Share

  188. MIAO Y, Qian S, Gao L, Zhou Z, et al
    Prognostic impacts of RHOA G17V mutation in cell-free DNA assessed by droplet digital polymerase chain reaction in patients with angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2025 Apr 7. doi: 10.1111/bjh.20071.
    >> Share

  189. LOPEDOTE P, Shouse G, Puverel S, Muir A, et al
    A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma.
    Br J Haematol. 2025 Apr 2. doi: 10.1111/bjh.20041.
    >> Share

  190. GIORDANO C, Picardi M, Pugliese N, Vincenzi A, et al
    Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged
    Br J Haematol. 2025 Apr 2. doi: 10.1111/bjh.20053.
    >> Share

    March 2025
  191. PIEROG O, Craig T, Jennings J, Borowitz MJ, et al
    The real-world application of T-cell receptor constant beta-1 chain antibody assay in cutaneous T-cell lymphoma.
    Br J Haematol. 2025 Mar 24. doi: 10.1111/bjh.20060.
    >> Share

  192. BRAY JS, Thomas GR, Smith VM, Wright A, et al
    In vitro comparison of CD20xCD3 biosimilar antibodies against diffuse large B-cell lymphoma (DLBCL) cell lines with different levels of expression of CD20.
    Br J Haematol. 2025 Mar 3. doi: 10.1111/bjh.20033.
    >> Share

  193. MOZAS P, Ould Ammar R, Chartier L, Nastoupil L, et al
    A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis.
    Br J Haematol. 2025 Mar 3. doi: 10.1111/bjh.20038.
    >> Share

  194. MALLET V, Torres HA
    Hepatitis E virus infection after CAR T-cell treatment: An important complication in patients already facing significant health challenges.
    Br J Haematol. 2025;206:1020-1021.
    >> Share

    February 2025
  195. MATO S, Carita L, Colmenero A, Andres M, et al
    Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents.
    Br J Haematol. 2025 Feb 26. doi: 10.1111/bjh.20012.
    >> Share

  196. ZHAO J, Liu TF, Wu KF, Yang LC, et al
    Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups.
    Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20011.
    >> Share

  197. WANG G, Wang F
    Immunoglobulin inclusions were released from lymphoma cells and deposited as cryoglobulin crystals in a peripheral blood film.
    Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20005.
    >> Share

  198. KOH YK, Yoon SH, Kang SH, Koh KN, et al
    Immunosuppressive therapy as first-line and relapse treatment in paediatric subcutaneous panniculitis-like T-cell lymphoma.
    Br J Haematol. 2025 Feb 16. doi: 10.1111/bjh.20014.
    >> Share

  199. IVANOVA VS, Menter T, Cui N, Leary P, et al
    Distinct subtypes of post-transplant lymphoproliferative disorders: CHIP-like mutations in early lesions and substantial mutational differences between EBV-positive and EBV-negative diffuse large B-cell lymphomas.
    Br J Haematol. 2025;206:484-504.
    >> Share

  200. EL-GALALY TC, Roug AS, Kristensen DT
    A successful clinical trial ecosystem offers equal opportunities for all citizens.
    Br J Haematol. 2025;206:788-789.
    >> Share

    January 2025
  201. DRAGOI D, Cusworth S, Oldham L, Sanderson R, et al
    CAR T access and outcomes in large B-cell lymphoma according to ethnicity and socioeconomic deprivation in the UK.
    Br J Haematol. 2025 Jan 16. doi: 10.1111/bjh.19997.
    >> Share

  202. SHIWAKU T, Tamefusa K, Ishida H, Fujiwara K, et al
    Paediatric anaplastic large-cell lymphoma with cardiac tamponade.
    Br J Haematol. 2025 Jan 12. doi: 10.1111/bjh.19980.
    >> Share

  203. CHIRIAC R
    Concomitant HIV-associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation.
    Br J Haematol. 2025 Jan 12. doi: 10.1111/bjh.19971.
    >> Share

  204. MUNAKATA W, Kumode T, Goto H, Fukuhara N, et al
    A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study.
    Br J Haematol. 2025 Jan 8. doi: 10.1111/bjh.19994.
    >> Share

  205. LEW-DERIVRY L, Chevillon F, Brice P, Bigenwald C, et al
    Should adolescents and young adults with Hodgkin lymphoma be treated as children or adults?
    Br J Haematol. 2025 Jan 5. doi: 10.1111/bjh.19985.
    >> Share

  206. LIN J, Mu Y, Liu L, Meng Y, et al
    Machine learning based on multiplatform tests assists in subtype classification of mature B-cell neoplasms.
    Br J Haematol. 2025;206:224-234.
    >> Share

  207. CAPES A, Morin A, Banet A, Suner L, et al
    Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids.
    Br J Haematol. 2025;206:180-185.
    >> Share

    December 2024
  208. STELLA F, Chiappella A, Magni M, Bonifazi F, et al
    Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.
    Br J Haematol. 2024 Dec 22. doi: 10.1111/bjh.19961.
    >> Share

  209. ZAMMAR G, Cheah CY
    Treating asymptomatic follicular lymphoma: What is the score?
    Br J Haematol. 2024 Dec 18. doi: 10.1111/bjh.19949.
    >> Share

  210. DE LA IGLESIA-SAN SEBASTIAN I, Lopez-Esteban M, Bastos-Oreiro M, Fernandez de Cordoba-Onate S, et al
    Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy.
    Br J Haematol. 2024 Dec 12. doi: 10.1111/bjh.19916.
    >> Share

  211. STRATI P, Agajanian R, Lossos IS, Coleman M, et al
    Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).
    Br J Haematol. 2024 Dec 12. doi: 10.1111/bjh.19951.
    >> Share

  212. CHOY J, Lewis KL
    In the SARS-CoV-2 era, do we need to be afraid of obinutuzumab?
    Br J Haematol. 2024;205:2113-2115.
    >> Share

  213. CALIMERI T, Ferreri AJM
    CNS prophylaxis in large B-cell lymphomas: A balance with three pans.
    Br J Haematol. 2024;205:2116-2118.
    >> Share

    November 2024
  214. MARZOLINI MAV, Qian W, Clifton-Hadley L, Patrick P, et al
    Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting.
    Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19918.
    >> Share

  215. JONES DA, Spencer K, Ramroth J, Probert J, et al
    Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England.
    Br J Haematol. 2024 Nov 27. doi: 10.1111/bjh.19907.
    >> Share

  216. SCHENA A, Quaglia FM, Parisi A, Ferrarini I, et al
    Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma.
    Br J Haematol. 2024 Nov 13. doi: 10.1111/bjh.19883.
    >> Share

  217. SCHWARZ M, Mozayani B, Trauner M, Stattermayer AF, et al
    Chronic hepatitis E in a patient after chimeric antigen receptor-T-cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis.
    Br J Haematol. 2024 Nov 7. doi: 10.1111/bjh.19892.
    >> Share

  218. KIM JL, Villa D, Tonseth RP, Gerrie AS, et al
    Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases.
    Br J Haematol. 2024 Nov 7. doi: 10.1111/bjh.19859.
    >> Share

  219. BARRETT A, Shah N, Chadwick A, Burns D, et al
    Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper.
    Br J Haematol. 2024 Nov 6. doi: 10.1111/bjh.19840.
    >> Share

  220. LI JR, Shaw VR, Parthasarathy A, Li Y, et al
    Prognostic stratification in DLBCL patients with aberrant MYC gene.
    Br J Haematol. 2024;205:1782-1793.
    >> Share

  221. CAMPBELL BA, Dobos G, Haider Z, Bagot M, et al
    Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapies.
    Br J Haematol. 2024;205:1825-1829.
    >> Share

    October 2024
  222. KARSTEN IE, Shumilov E, Schmitz N, Lenz G, et al
    Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs.
    Br J Haematol. 2024 Oct 28. doi: 10.1111/bjh.19860.
    >> Share

  223. FUKUOKA K, Zhao J, Oshima K, Honda M, et al
    Isolated testicular second-relapsed T-lymphoblastic lymphoma after allogeneic stem cell transplantation: Therapeutic implication from sequential molecular genetic analysis.
    Br J Haematol. 2024 Oct 27. doi: 10.1111/bjh.19870.
    >> Share

  224. ALBANO D
    (18)F-FDG PET/CT impact in grade 3B follicular lymphoma.
    Br J Haematol. 2024 Oct 27. doi: 10.1111/bjh.19852.
    >> Share

  225. JIANG L, Dreyling M, Hermine O, Mansmann U, et al
    Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network.
    Br J Haematol. 2024 Oct 23. doi: 10.1111/bjh.19854.
    >> Share

  226. YOSHIMITSU M, Tanaka T, Nakano N, Kato K, et al
    Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2024 Oct 19. doi: 10.1111/bjh.19835.
    >> Share

  227. BUCCHERI V, Moreira FR, Biasoli I, Castro N, et al
    External validation and calibration of the HoLISTIC Consortium's advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in the Brazilian Hodgkin lymphoma registry.
    Br J Haematol. 2024 Oct 17. doi: 10.1111/bjh.19824.
    >> Share

  228. LE GALLO M, Rose J, Safa F, Cottin L, et al
    Bone marrow metastasis of rhabdomyosarcoma mimicking high-grade lymphoma in a young man.
    Br J Haematol. 2024 Oct 15. doi: 10.1111/bjh.19795.
    >> Share

  229. CHIRIAC R, Baseggio L
    Monomorphic epitheliotropic intestinal T-cell lymphoma involving the aqueous humour.
    Br J Haematol. 2024 Oct 14. doi: 10.1111/bjh.19806.
    >> Share

  230. BARRACLOUGH A, Lee ST, Villa D, Hapgood G, et al
    The value of semiquantitative PET features and end-of-therapy PET in grade 3B follicular lymphoma.
    Br J Haematol. 2024 Oct 13. doi: 10.1111/bjh.19823.
    >> Share

  231. SHERIF M, Schafer H, Scharf S, van Oostendorp V, et al
    EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type.
    Br J Haematol. 2024 Oct 2. doi: 10.1111/bjh.19778.
    >> Share

  232. WU S, Luo Q, Li F, Zhang S, et al
    Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms.
    Br J Haematol. 2024;205:1361-1373.
    >> Share

  233. BARONE A, Chiappella A, Casadei B, Bramanti S, et al
    Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study.
    Br J Haematol. 2024;205:1356-1360.
    >> Share

    September 2024
  234. LIU J, Gao F, Zhang T, Wang J, et al
    Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis.
    Br J Haematol. 2024 Sep 26. doi: 10.1111/bjh.19770.
    >> Share

  235. STRATI P, Champion R, Coleman M, Smith SM, et al
    Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.
    Br J Haematol. 2024 Sep 22. doi: 10.1111/bjh.19787.
    >> Share

  236. MUNSHI M, Liu X, Kofides A, Tsakmaklis N, et al
    ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.
    Br J Haematol. 2024 Sep 18. doi: 10.1111/bjh.19756.
    >> Share

  237. KURUVILLA J, Rushton C, Villa D, Aslam M, et al
    A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma.
    Br J Haematol. 2024 Sep 12. doi: 10.1111/bjh.19764.
    >> Share

  238. NARESH KN
    Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
    Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754.
    >> Share

  239. FORSGREN E, Ekberg S, Smedby KE, Nylund P, et al
    Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden: A comparison with nationwide registers.
    Br J Haematol. 2024 Sep 3. doi: 10.1111/bjh.19732.
    >> Share

  240. SHOUVAL R, Goldman A, Flynn JR, El-Moghraby A, et al
    Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile.
    Br J Haematol. 2024;205:978-989.
    >> Share

    August 2024
  241. PIGNOT PE, Bahri H, Malartre S, Morisset S, et al
    Impact of the total lesion glycolysis (TLG) in predicting response of follicular lymphoma to rituximab.
    Br J Haematol. 2024 Aug 27. doi: 10.1111/bjh.19724.
    >> Share

  242. KUMAR EA, Korfi K, Bewicke-Copley F, Close K, et al
    CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.
    Br J Haematol. 2024 Aug 26. doi: 10.1111/bjh.19671.
    >> Share

  243. WILSON MR, Cwynarski K, Eyre TA, Smith J, et al
    Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper.
    Br J Haematol. 2024 Aug 11. doi: 10.1111/bjh.19686.
    >> Share

  244. HERSHENFELD SA, Tobin JWD, Shelton V, Calvente L, et al
    Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.
    Br J Haematol. 2024 Aug 7. doi: 10.1111/bjh.19698.
    >> Share

  245. YI JH, Kim SJ, Yang DH, Do YR, et al
    Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma.
    Br J Haematol. 2024 Aug 5. doi: 10.1111/bjh.19659.
    >> Share

  246. AARNIVALA H, Giertz M, Michelsen SW, Bjorklund C, et al
    Radiological follow-up of osteonecrosis lesions in children and adolescents with Hodgkin lymphoma.
    Br J Haematol. 2024 Aug 3. doi: 10.1111/bjh.19687.
    >> Share

  247. CORAZZELLI G, Cuccaro A, Morelli E, Arcamone M, et al
    Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVD(DD-DI) phase II study.
    Br J Haematol. 2024 Aug 1. doi: 10.1111/bjh.19646.
    >> Share

  248. MUHSEN IN, Heslop HE
    Time to optimize vaccination strategies in blood cancer patients.
    Br J Haematol. 2024;205:406-408.
    >> Share

    July 2024
  249. SPRIANO F, Tarantelli C, Cascione L, Gaudio E, et al
    Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents.
    Br J Haematol. 2024 Jul 30. doi: 10.1111/bjh.19658.
    >> Share

  250. BALZAROTTI M, Bagnoli F
    Rolling the DICEP on lymphoma salvage treatments? Choose wisely.
    Br J Haematol. 2024 Jul 27. doi: 10.1111/bjh.19655.
    >> Share

  251. KAMIJO K, Shimomura Y, Kim SW, Ohigashi H, et al
    Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024 Jul 24. doi: 10.1111/bjh.19651.
    >> Share

  252. GALLAMINI A, Filippi A, Camus V, Vassilakopoulos TP, et al
    Toward a paradigm shift in prognostication and treatment of early-stage Hodgkin lymphoma.
    Br J Haematol. 2024 Jul 22. doi: 10.1111/bjh.19657.
    >> Share

  253. PINTO A, Caltagirone M, Battista M, Gazzoli GC, et al
    Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.
    Br J Haematol. 2024 Jul 22. doi: 10.1111/bjh.19661.
    >> Share

  254. CARLO-STELLA C
    Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
    Br J Haematol. 2024;205:17-19.
    >> Share

  255. GRIGG S, Minson A, Prins E, Dickinson MJ, et al
    Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high.
    Br J Haematol. 2024;205:122-126.
    >> Share

  256. CIVALLERO M, Schroers-Martin JG, Horwitz S, Manni M, et al
    Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project.
    Br J Haematol. 2024;205:166-174.
    >> Share

    June 2024
  257. CAVALLO F, Clerico M, Lucchini E, Castiglione A, et al
    Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.
    Br J Haematol. 2024 Jun 28. doi: 10.1111/bjh.19617.
    >> Share

  258. PRIOR D, Schmitt AD, Louissaint A, Mata DA, et al
    Large B-cell lymphoma with mystery rearrangement: Applying Hi-C to the detection of clinically relevant structural abnormalities.
    Br J Haematol. 2024 Jun 25. doi: 10.1111/bjh.19611.
    >> Share

  259. LIM YJ, Ward V, Brown A, Phillips E, et al
    Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
    Br J Haematol. 2024 Jun 13. doi: 10.1111/bjh.19562.
    >> Share

  260. ROSSETTI S, Juul SJ, Eriksson F, Warming PE, et al
    Long-term cause-specific mortality in adolescent and young adult Hodgkin lymphoma patients treated with contemporary regimens-A nationwide Danish cohort study.
    Br J Haematol. 2024 Jun 12. doi: 10.1111/bjh.19586.
    >> Share

  261. SCIARRA R, Merli M, Cristinelli C, Lucioni M, et al
    Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection.
    Br J Haematol. 2024;204:2242-2253.
    >> Share

    May 2024
  262. SHORTT J, Opat S
    Large cell lymphoma through a liquid lens.
    Br J Haematol. 2024 May 30. doi: 10.1111/bjh.19502.
    >> Share

  263. ALCOCEBA M, Stewart JP, Garcia-Alvarez M, Diaz LG, et al
    Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease.
    Br J Haematol. 2024 May 29. doi: 10.1111/bjh.19458.
    >> Share

  264. STEWART DA, Kuruvilla J, Lee D, Dudebout JJ, et al
    Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide,
    Br J Haematol. 2024 May 27. doi: 10.1111/bjh.19555.
    >> Share

  265. OTHMAN T, Baird JH, Pak S, Mei M, et al
    Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
    Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19521.
    >> Share

  266. EPPERLA N, Hashmi H, Ahn KW, Allbee-Johnson M, et al
    Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis.
    Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19569.
    >> Share

  267. RUPAKUMAR T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, et al
    Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.
    Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19559.
    >> Share

  268. HOFER KD, Wolfensberger N, Bachofner A, Schneidawind C, et al
    B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphoma.
    Br J Haematol. 2024 May 23. doi: 10.1111/bjh.19571.
    >> Share

  269. COELHO J, Roush SM, Xu AM, Puranam K, et al
    HIV and prior exposure to antiretroviral therapy alter tumour composition and tumour: T-cell associations in diffuse large B-cell lymphoma.
    Br J Haematol. 2024 May 20. doi: 10.1111/bjh.19531.
    >> Share

  270. BROCKELMANN PJ
    Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma.
    Br J Haematol. 2024 May 16. doi: 10.1111/bjh.19534.
    >> Share

  271. KUCZMARSKI TM, Lynch RC
    Managing common toxicities associated with checkpoint inhibitor and chemotherapy combinations for untreated classic Hodgkin lymphoma.
    Br J Haematol. 2024 May 2. doi: 10.1111/bjh.19478.
    >> Share

  272. SOUMERAI JD, Diefenbach CS, Jagadeesh D, Asch A, et al
    Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
    Br J Haematol. 2024;204:1762-1770.
    >> Share

  273. BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
    The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
    Br J Haematol. 2024;204:1649-1659.
    >> Share

  274. FARDELLA E, Zanirato G, Magni M, Caldarelli N, et al
    Prognostic impact of pretreatment cell-free DNA concentration in newly diagnosed peripheral T-cell lymphomas.
    Br J Haematol. 2024;204:1752-1756.
    >> Share

    April 2024
  275. VANDTVED JH, Ovlisen AK, Baech J, Weinrich UM, et al
    Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study.
    Br J Haematol. 2024 Apr 29. doi: 10.1111/bjh.19475.
    >> Share

  276. HUO W, Gao L, Song K, Huang J, et al
    Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
    Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19481.
    >> Share

  277. LEWIS CS, Joy G, Jensen P, Barraclough A, et al
    Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study.
    Br J Haematol. 2024 Apr 17. doi: 10.1111/bjh.19470.
    >> Share

  278. CAO XY, Zhang JP, Lu Y, Zhao YL, et al
    A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen r
    Br J Haematol. 2024 Apr 13. doi: 10.1111/bjh.19445.
    >> Share

  279. GANAPATHI KA, Nicolae A, Egan C, Geng H, et al
    Peripheral T-cell lymphomas expressing CD30 and CD15 expand the spectrum of anaplastic large cell lymphoma, ALK-negative.
    Br J Haematol. 2024 Apr 12. doi: 10.1111/bjh.19442.
    >> Share

  280. KUHNL A, Roddie C, Kirkwood AA, Chaganti S, et al
    Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.
    Br J Haematol. 2024 Apr 9. doi: 10.1111/bjh.19453.
    >> Share

  281. MARTYNCHYK A, Hawkes EA
    Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma-Moving to a model where less can be more.
    Br J Haematol. 2024 Apr 6. doi: 10.1111/bjh.19456.
    >> Share

  282. ATALLAH-YUNES SA, Habermann TM, Khurana A
    Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation.
    Br J Haematol. 2024 Apr 5. doi: 10.1111/bjh.19425.
    >> Share

  283. MILROD CJ, Kim KW, Raker C, Ollila TA, et al
    Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.
    Br J Haematol. 2024 Apr 4. doi: 10.1111/bjh.19449.
    >> Share

  284. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
    Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1367-1374.
    >> Share

  285. MOULIN C, Beaupain B, Suarez F, Bertrand Y, et al
    CXCR4 WHIM syndrome is a cancer predisposition condition for virus-induced malignancies.
    Br J Haematol. 2024;204:1383-1392.
    >> Share

    March 2024
  286. MERLI M, Costantini A, Tafuri S, Bavaro DF, et al
    Management of vaccinations in patients with non-Hodgkin lymphoma.
    Br J Haematol. 2024 Mar 26. doi: 10.1111/bjh.19422.
    >> Share

  287. MANOS K, Churilov L, Grigg A, Di Ciaccio P, et al
    Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
    Br J Haematol. 2024 Mar 14. doi: 10.1111/bjh.19407.
    >> Share

  288. BAPTISTA P, Aguiar E, Fonseca E, Pinto R, et al
    Intravascular large B-cell lymphoma presenting with haemophagocytic syndrome.
    Br J Haematol. 2024 Mar 12. doi: 10.1111/bjh.19350.
    >> Share

  289. LI X, Gao F, Meng X, Zhang X, et al
    Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma.
    Br J Haematol. 2024 Mar 6. doi: 10.1111/bjh.19393.
    >> Share

  290. NGUYEN PC, Nguyen T, Wilson C, Tiong IS, et al
    Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.
    Br J Haematol. 2024;204:910-920.
    >> Share

  291. AL-MASHHADI AL, Jakobsen LH, Brown P, Gang AO, et al
    Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas.
    Br J Haematol. 2024;204:839-848.
    >> Share

    February 2024
  292. BISHTON MJ, Crooks CJ, Card TR, West J, et al
    Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma.
    Br J Haematol. 2024 Feb 29. doi: 10.1111/bjh.19371.
    >> Share

  293. YE P, Cheng Y, Lian J, Tong H, et al
    Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study.
    Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19367.
    >> Share

  294. STEPANISHYNA Y, Manni M, Civallero M, Shokun N, et al
    Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021.
    Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19352.
    >> Share

  295. FLORA DR, Parsons SK, Liu N, Yu KS, et al
    Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey.
    Br J Haematol. 2024 Feb 7. doi: 10.1111/bjh.19307.
    >> Share

  296. VOGELSBERG A, Harland L, Borgmann V, Otto F, et al
    Clonal haematopoiesis: A common progenitor for cytotoxic peripheral T-cell lymphoma and angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2024 Feb 7. doi: 10.1111/bjh.19335.
    >> Share

  297. BEDNARSKA K, Chowdhury R, Tobin JWD, Swain F, et al
    Epstein-Barr virus-associated lymphomas decoded.
    Br J Haematol. 2024;204:415-433.
    >> Share

  298. WANG Z, Fan Z, Wu Z, Xuan L, et al
    PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:628-637.
    >> Share

  299. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;204:561-565.
    >> Share

  300. PELLICCIA S, Rogges E, Cardoni A, Lopez G, et al
    The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features.
    Br J Haematol. 2024;204:534-547.
    >> Share

    January 2024
  301. LUEDERSEN J, Stadt UZ, Richter J, Oschlies I, et al
    Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.
    Br J Haematol. 2024 Jan 26. doi: 10.1111/bjh.19308.
    >> Share

  302. YANG P, Cai M, Cao Y, Fan S, et al
    Up-front autologous stem cell transplant in peripheral T-cell lymphoma patients achieving complete response after first-line treatment: A multicentre real-world analysis.
    Br J Haematol. 2024 Jan 25. doi: 10.1111/bjh.19317.
    >> Share

  303. ABEYAKOON C, Gregory GP
    New standards of care for treatment of diffuse large B-cell lymphoma.
    Br J Haematol. 2024 Jan 22. doi: 10.1111/bjh.19295.
    >> Share

  304. FOX CP, Chaganti S, McIlroy G, Barrington SF, et al
    The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2024 Jan 21. doi: 10.1111/bjh.19273.
    >> Share

  305. LIAPIS K, Misidou C, Spanoudakis E, Kotsianidis I, et al
    Concurrent visceral leishmaniasis and diffuse large B-cell lymphoma of the bone marrow.
    Br J Haematol. 2024 Jan 7. doi: 10.1111/bjh.19283.
    >> Share

  306. WALEWSKA R, Eyre TA, Barrington S, Brady J, et al
    Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline.
    Br J Haematol. 2024;204:86-107.
    >> Share

  307. VISCO C
    Letting the mantle out of the bag.
    Br J Haematol. 2024;204:11-13.
    >> Share

  308. KHWAJA J, Vos JMI, Pluimers TE, Japzon N, et al
    Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia.
    Br J Haematol. 2024;204:177-185.
    >> Share

  309. DODERO A, Bramanti S, Di Trani M, Pennisi M, et al
    Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
    Br J Haematol. 2024;204:151-159.
    >> Share

    December 2023
  310. BAECH J, Husby S, Trab T, Kragholm K, et al
    Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study.
    Br J Haematol. 2023 Dec 28. doi: 10.1111/bjh.19272.
    >> Share

  311. MOTOMURA Y, Yoshifuji K, Tachibana T, Takase H, et al
    Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma.
    Br J Haematol. 2023 Dec 22. doi: 10.1111/bjh.19266.
    >> Share

  312. TOTARO A, Calafiore AM, Sacra C, Magnano D, et al
    Huge right atrial mass in mantle cell lymphoma.
    Br J Haematol. 2023 Dec 21. doi: 10.1111/bjh.19258.
    >> Share

  313. JIN X, Zhou W, Jiang H, Chen Z, et al
    A case of a large number of Reed-Sternberg cells in pleural fluid following treatment of classical Hodgkin lymphoma.
    Br J Haematol. 2023 Dec 20. doi: 10.1111/bjh.19260.
    >> Share

  314. MASRONI MSB, Leong SM, Cheng H, Lim GS, et al
    miR-101-5p modulation of CD47 in diffuse large B-cell lymphoma: Implications for anti-CD47 immunotherapy and prognostication.
    Br J Haematol. 2023 Dec 12. doi: 10.1111/bjh.19264.
    >> Share

  315. FLOSPERGHER E, Marino F, Calimeri T, Cangi MG, et al
    Primary central nervous system marginal zone lymphoma.
    Br J Haematol. 2023 Dec 6. doi: 10.1111/bjh.19238.
    >> Share

  316. WU JF, Abid H, Szabo A, Abid MB, et al
    Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
    Br J Haematol. 2023;203:e117-e120.
    >> Share

    November 2023
  317. SARTORI G, Tarantelli C, Spriano F, Gaudio E, et al
    The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
    Br J Haematol. 2023 Nov 27. doi: 10.1111/bjh.19218.
    >> Share

  318. WATANABE T, Tobinai K, Wakabayashi M, Maruyama D, et al
    R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
    Br J Haematol. 2023 Nov 23. doi: 10.1111/bjh.19213.
    >> Share

  319. HEINI AD, Bacher U, Pabst T
    Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL).
    Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19195.
    >> Share

  320. CARACCIOLO D, Polera N, Belmonte B, Conforti F, et al
    UMG1/CD3epsilon-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
    Br J Haematol. 2023 Nov 14. doi: 10.1111/bjh.19183.
    >> Share

  321. PEDERSEN MA, Gormsen LC, Jakobsen LH, Eyre TA, et al
    The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study.
    Br J Haematol. 2023 Nov 13. doi: 10.1111/bjh.19194.
    >> Share

  322. GALLI E, Bellesi S, Pansini I, Di Cesare G, et al
    The CD4/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity.
    Br J Haematol. 2023;203:564-570.
    >> Share

  323. WATANABE M, Kanda J, Fukuda T, Uchida N, et al
    Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy.
    Br J Haematol. 2023;203:446-459.
    >> Share

  324. LIM MS
    Haematolymphoid malignancies: It is not important WHO we are but WHERE we go from here.
    Br J Haematol. 2023;203:349-350.
    >> Share

  325. FALINI B, Lazzi S, Pileri S
    A comparison of the International Consensus and 5th WHO classifications of T-cell lymphomas and histiocytic/dendritic cell tumours.
    Br J Haematol. 2023;203:369-383.
    >> Share

    October 2023
  326. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
    The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
    >> Share

  327. STUVER R, Noy A, Vardhana SA, Zelenetz AD, et al
    Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19178.
    >> Share

  328. MINSON A, Hamad N, Di Ciaccio P, Talaulikar D, et al
    Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.
    Br J Haematol. 2023 Oct 30. doi: 10.1111/bjh.19179.
    >> Share

  329. GONG IY, Prica A, Ante Z, Calzavara A, et al
    Indolent lymphoma care delivery and outcomes during the COVID-19 pandemic in Ontario, Canada.
    Br J Haematol. 2023 Oct 27. doi: 10.1111/bjh.19166.
    >> Share

  330. RAMSOWER CA, Rosenthal A, Robetorye RS, Mwangi R, et al
    Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
    Br J Haematol. 2023 Oct 25. doi: 10.1111/bjh.19153.
    >> Share

  331. EYRE TA, Bishton MJ, McCulloch R, O'Reilly M, et al
    Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline.
    Br J Haematol. 2023 Oct 25. doi: 10.1111/bjh.19131.
    >> Share

  332. CALABRETTA E, di Trani M, Corrado F, Sollini M, et al
    Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 18. doi: 10.1111/bjh.19162.
    >> Share

  333. BOYLE S, Roddie C, O'Reilly M, Menne T, et al
    Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
    Br J Haematol. 2023 Oct 17. doi: 10.1111/bjh.19157.
    >> Share

  334. KYVSGAARD ER, Riley C, Clausen MR, Harslof M, et al
    Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy.
    Br J Haematol. 2023 Oct 13. doi: 10.1111/bjh.19156.
    >> Share

  335. MAMLOUK O, Strati P, Feng L, Sun R, et al
    Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function.
    Br J Haematol. 2023 Oct 11. doi: 10.1111/bjh.19152.
    >> Share

  336. CONTARINI G, Carraro E, Lovisa F, Martire G, et al
    Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series.
    Br J Haematol. 2023 Oct 11. doi: 10.1111/bjh.19151.
    >> Share

  337. LIU H, He Z, Gui R, Guo J, et al
    Stratified management based on surface antibody for the prevention of hepatitis B virus reactivation in lymphoma patients.
    Br J Haematol. 2023 Oct 6. doi: 10.1111/bjh.19140.
    >> Share

  338. GAO J, Dahiya S, Patel SA
    Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas.
    Br J Haematol. 2023;203:161-168.
    >> Share

  339. CHUNG EYL, Sartori G, Ponzoni M, Cascione L, et al
    ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells.
    Br J Haematol. 2023;203:244-254.
    >> Share

    September 2023
  340. LEWIS KL, Cheah CY
    Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect.
    Br J Haematol. 2023 Sep 24. doi: 10.1111/bjh.19095.
    >> Share

  341. HAYASHI K, Koyama D, Sato Y, Fukatsu M, et al
    Lymphoplasmacytic lymphoma presenting cold agglutinin syndrome: Clonal expansion of KMT2D and IGHV4-34 mutations after COVID-19.
    Br J Haematol. 2023 Sep 11. doi: 10.1111/bjh.19106.
    >> Share

  342. XIONG J, Zhao WL
    A novel SLC1A1-RIC1 fusion sensitive to asparaginase-based therapy in natural killer/T-cell lymphoma.
    Br J Haematol. 2023 Sep 1. doi: 10.1111/bjh.19066.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016